PT514 – Breaking Through Bureaucracy: Can D.C. Embrace Evidence-Based Drug Policy?, with Senator Tom Daschle and Charlie Panfil

In this episode, Joe interviews two members of The Daschle Group: Founder and CEO, Senator Tom Daschle; and Public Policy Advisor, Charlie Panfil. As Senator Daschle served in the House of Representatives for eight years (starting in 1978) and the Senate for 21, he was deep in the War on Drugs at its peak, and thankfully, as seen with so many of his constituents in recent years, the data and personal stories of so many healed people has broken through the propaganda and made him a strong advocate for psychedelic-assisted therapy. While minds are changing and progress is happening before our eyes (the majority of substances the FDA is currently researching for psychiatric indications contain some form of psychedelic ingredient), government bureaucracy, a severe lack of communication between the FDA and DEA, and decades of lies are still massive roadblocks. How do we address all of this while advancing research? They discuss: The need to develop a partnership between the public and private sectors, mostly for the cost of treatments The DEA's place in all of this: If they're essentially a law enforcement agency, why are they involved in the safety and efficacy of medical treatments? The STATES Act, the Breakthrough Therapies Act, and how they can affect research Why we need to move past relying on opioids, and instead, embrace a science-based drug policy and more! For links, head to the show notes page.